IMMUNEONCO-B (01541) rose over 10% in morning trading. As of the time of writing, the stock was up 8.63%, trading at HKD 6.67, with a turnover of HKD 11.1965 million.

The company announced that the group has received approval from the National Medical Products Administration (NMPA) of China to conduct a clinical trial for IMM01 (Tidapaxic) for the treatment of atherosclerosis.

It is reported that the group holds the global intellectual property rights and commercialization rights for IMM01 (Tidapaxic).

As of the date of this announcement, for IMM01 (Tidapaxic), the group holds one patent family, which includes granted patents in China, the United States, Japan, and the European Union.

Guoyuan International released a research report stating that the company recently regained global rights for IMM2510 and IMM27M, reclaiming leadership in overseas clinical development, which will accelerate the global development pace.

The clinical data for 2510 is excellent, with a good safety profile and clear differentiated advantages.

The company's R&D pipeline continues to expand, enhancing its risk resistance capability; the CD47/CD20 bispecific antibody (IMM0306) has shown outstanding clinical efficacy data and is expected to become a blockbuster drug in the autoimmune field.

The company is a global innovation leader in CD47 fusion proteins, with a rich pipeline offering broad application prospects in the fields of oncology, autoimmune diseases, and cardiovascular diseases.

With a current market capitalization of only HKD 2.7 billion, the stock is severely undervalued, and it is recommended to maintain active attention.